The peptidyl-proplyl-isomerase, PIN1, upregulates b-catenin by inhibiting its interaction with APC. b-catenin accumulation occurs in about 70% of hepatocellular carcinoma (HCC), of which only 20% are due to b-catenin mutations. The role of PIN1 in b-catenin upregulation in HCC was investigated. PIN1 was shown to be overexpressed in more than 50% of HCC. All cases with PIN1 overexpression also showed b-catenin accumulation, with 68% of cases showing concomitant b-catenin and cyclin D1 accumulation. PIN1 was shown to contribute to b-catenin and cyclin D1 overexpression directly by in vitro cell-line transfection experiments. Finally, we showed that PIN1 overexpression and b-catenin gene mutations appeared to be mutually exclusive events, leading to b-catenin accumulation in HCC. These results showed that PIN1 overexpression leading to b-catenin accumulation might be a critical event in hepatocarcinogenesis, and that PIN1 is a potential target for therapeutic intervention in HCC.
Introduction, results and discussion
The Wingless/Wnt pathway, first shown to play a pivotal role in the colorectal carcinogenesis, has also been found recently to be inappropriately activated in human HCC (de La Coste et al., 1998) . b-catenin is an important downstream effector of the Wnt pathway. Its level is regulated via phosphorylation by GSK-3b in a multimeric protein complex comprising b-catenin, GSK3b, APC and AXIN proteins (Ikeda et al., 1998) . Phosphorylated b-catenin is then destined to degradation through the ubiquitin-proteasome system (Aberle et al., 1997; Kitagawa et al., 1999) . As a result of b-catenin gene mutations, b-catenin phosphorylation is impaired, leading to the stabilization of the b-catenin protein and its translocation from the cell cytosol to the nucleus (Morin et al., 1997) . The nuclear accumulation of b-catenin activates the transcription of genes critical for cell proliferation and transformation, such as cyclin D1 and c-myc (He et al., 1998; Shtutman et al., 1999) . Somatic mutations of b-catenin have been shown to occur in approximately 10-20% of HCC (de La Coste et al., 1998; Miyoshi et al., 1998) . However, the percentage of HCC with b-catenin protein accumulation is much higher, with immunohistochemical study showing b-catenin overexpression in 50-83% of HCCs (Ihara et al., 1996; Huang et al., 1999) . AXIN1 and AXIN2 gene mutations are unlikely to contribute significantly, as these have only been reported in about 5-10% of HCC (Taniguchi et al., 2002) . Furthermore, inactivating mutations of the APC gene are rarely identified in HCC (Chen et al., 1998) . Therefore, other undefined mechanisms are involved in the b-catenin stabilization and accumulation.
PIN1, a peptidyl-proplyl-isomerase, is one of the potential candidates for b-catenin dysregulation, as it has been shown to upregulate b-catenin level by inhibiting its interaction with APC . In addition to the aberrations in the Wnt pathway, cyclin D1 overexpression also plays an important role in the development of HCC (Nishida et al., 1994; Deane et al., 2001) . Interestingly, PIN1 also upregulates cyclin D1 via the increase in b-catenin, the enhancement of the transactivating activity of c-Jun and the post-translational stabilization of cyclin D1 Liou et al., 2002) . These observations suggest that PIN1 may be potentially involved in hepatocarcinogenesis. Here, we report the overexpression of PIN1 and its relation with b-catenin and cyclin D1 levels in HCC, and discuss its possible role in hepatocarcinogenesis.
Fresh tumors and their corresponding nontumorous liver tissue samples were obtained from surgical specimens of patients with HCC undergoing hepatectomy at Queen Mary Hospital, Hong Kong from 1997 to 2001.
Archival HCC and noncancerous liver tissue samples were also studied using immunohistochemistry. We showed that PIN1 was overexpressed at both mRNA and protein levels in HCC tumors as compared with their nontumorous counterpart. As shown in Figure 1a , the level of PIN1 mRNA in tumors was shown to exceed that in nontumor tissues in 20 of 38 tumors (53%) by semiquantitative RT-polymerase chain reaction (PCR). At the protein level, PIN1 overexpression was detected in 17 of 32 cases (53%) by Western blot analysis ( Figure 1b) and 37 of 60 tumors (62%) by immunohistochemistry. In tumors positive for PIN1 staining, the majority of cases exhibited both nuclear and cytoplasmic accumulation of the protein (Figure 2a ). In their Figure 1 Expression of PIN1, b-catenin and cyclin D1 in HCC. (a) Total cellular RNA was extracted from frozen tissues using TRIzol reagent according to the manufacturer's protocol (Gibco/BRL, Grand Island, NY, USA). Total RNA (2 mg) were reversely transcribed using Superscriptt First strand Synthesis System (Invitrogen, CA, USA). One-tenth of the cDNA was used for PCR. PCR was performed with AmpliTAq Gold Polymerase (Applied Biosystems, Foster City, CA, USA). For semiquantitative anaylsis, b-actin was used as an internal control. The sense and antisense primers (Invitrogen, CA, USA) were as follows: PIN1, 5 0 -AAG ATG GCG GAC GAG GAG-3 0 and 5 0 -CAC TCA GTG CGG AGG ATG AT-3 0 ; b-actin, 5 0 -CAC AGC AAG TGT GGC ATC CT-3 0 and 5 0 -GTT GAA GGT CTC AAA CAT GA-3 0 . PCR products were electrophoresed in 1% agarose gel and analysed using a gel documentation system. Tissue lysates were prepared from fresh or snap-frozen tissues by homogenization in standard lysis buffer (PBS containing 1% NP-40; 0.5% sodiuim deoxycholate; 0.1% SDS; and 1 mM phenylmethylsulfonyl fluoride, 25 mg/ml aprotinin and 1 mM sodium orthovanadate). Proteins (30 mg) were separated on a 12% SDS-PAGE gel and transferred onto a membrane using a semidry transfer apparatus. Membranes were then incubated at room temperature for 1 h in blocking solution (Tris-buffered saline containing 10% nonfat dried milk and 0.1% Tween-20), washed and probed with either polyclonal rabbit anti-PIN1 (Oncogene Research Products, San Diego, CA, USA), monoclonal mouse anti-b-catenin (Transduction Larboratories, La Jolla, CA, USA) or monoclonal mouse anti-cyclin D1 (Zymed Laboratories Inc., CA, USA). Monoclonal mouse anti-actin (Santa Cruz, CA, USA) served as an internal control. After washing, membranes were probed with the appropriate secondary antibodies and visualized with the enhanced chemiluminescence system (Amersham, Buckinghamshire, UK) according to the manufacturer's protocol Figure 2 Immunostaining for PIN1, b-catenin and cyclin D1 in one of the HCC samples. Formalin-fixed and paraffin-embedded HCC specimens were cut into 5 mm thick sections, mounted on slides, deparaffinized in xylene and rehydrated in serial dilutions of alcohol. Antigen retrieval was performed by microwave treatment for 20 min in 0.01 M citrate buffer (pH6.0). Endogenous peroxidase was quenched by treatment with 3% H 2 O 2 for 30 min, followed by blocking of endogenous biotin activity using a biotin blocking kit (DAKO Corporation, Carpinteria, CA, USA). Sections were incubated with the primary antibodies (Rabbit polyclonal antiPin1, 1 : 100, Oncogene Research Products, San Diego, CA, USA; mouse monoclonal anti-b-catenin, 1 : 200, Zymed Laboratories Inc., CA, USA; mouse monoclonal anti-cyclin D1, 1 : 200, DAKO Corporation, Carpinteria, CA, USA) for 1 h at room temperature, and probed with biotinylated goat-anti-mouse or goat-anti-rabbit Ig (DAKO Corporation, Carpinteria, CA, USA). Staining was performed with a strepavidin-biotin peroxidase kit (DAKO Corporation, Carpinteria, CA, USA) and sites of bound antibody were visualized using liquid DAB þ substrate-chromogen system (DAKO Corporation, Carpinteria, CA, USA). Control slides included in each experiment consisted of tissue previously shown to express the protein of interest as positive controls, and negative control with the primary antibody replaced by Tris-buffered saline. Histochemical scoring of PIN1 and b-catenin was defined as negative when the membranous and/or cytoplasmic straining was weak and similar to that of the adjacent non-neoplastic hepatocytes, and positive when the staining was stronger than the surrounding hepatocytes. For cyclin D1, only distinct nuclear staining was regarded as positive. respective nontumor counterpart, absent to very weak cytoplasmic expression of PIN1 was observed (Figure 2b) .
b-catenin and cyclin D1 expression was also analysed to assess their correlation with PIN1. b-catenin protein accumulation was detected in 21 of 32 (66%) and 42 of 60 (70%) tumors by Western blot analysis (Figure 1b) , and immunohistochemistry (Figure 2c) , respectively, which was comparable with the results from previous studies (Ihara et al., 1996; Huang et al., 1999) . Nuclear staining pattern of b-catenin was detected in six cases, with the rest showing strong staining in the cytoplasm and/or cytoplasmic membrane. Cyclin D1 levels were increased in 13 of the 32 cases (41%) by Western blot analysis (Figure 1b ) and in 25 of the 60 HCC samples (42%) by immunohistochemistry (Figure 2e) .
The association of PIN1, b-catenin and cyclin D1 levels is summarized in Table 1a . All cases with PIN1 overexpression by immunohistochemistry (n ¼ 37) had concomitant accumulation of the b-catenin protein (100%), and 25 (68%) had both b-catenin and cyclin D1 overexpression. PIN1 overexpression positively correlated with an increase in b-catenin and cyclin D1 protein levels as shown by statistical analysis (Table 1a) . There is one out of the 17 cases that have PIN1 overexpression but no b-catenin overexpression by Western blot (Table 1a) . On the other hand, this particular sample, by immunohistochemistry, did show convincing evidence of PIN1 overexpression and bcatenin accumulation. We do not have a good explanation for it, but a number of variables in human tissue specimen (a nonhomogeneous material, unlike a cell line) may contribute to it.
To show that PIN1 overexpression may lead directly to increases in b-catenin and cyclin D1 in HCC, a PIN1 cDNA expression construct was transfected into a human liver cell line, MIHA (Brown et al., 2000) . Western blot analysis confirmed a significant increase in b-catenin and cyclin D1 when PIN1 was overexpressed in the cell line, by both transient and stable transfection (Figure 3a) . In addition, the levels of PIN1 in the stably transfected MIHA clones positively correlated with b-catenin levels, that is, the higher the expression of PIN1, the greater the increase in the b-catenin levels (Figure 3b) . Using an antisense approach, other investigators have shown that downregulation of PIN1 in HeLa cell line led to a decrease in b-catenin levels . Furthermore, all tissues of PIN1 knockout mice have also been shown to have a lower b-catenin levels, compared to that of wild-type mice . Taking all data together, we believed that overexpression of PIN1 upregulates b-catenin levels in HCC in a direct manner.
Of all the 20 HCC samples with PIN1 overexpression as detected by semi-quantitative RT-PCR, no mutation of b-catenin was found. On the other hand, among the three samples with b-catenin protein accumulation but without PIN1 overexpression, two cases were found to have somatic mutations in exon 3 of b-catenin. Both were missense mutations at codon 45 (Ser45-Cys and Ser45-Pro), which resulted in the substitution of the serine residue, thus abrogating the phosphorylation site by GSK-3b (Miyoshi et al., 1998) . The results were summarized in Table 1b . Owing to the small number of HCC samples with b-catenin mutations detected in this study, immunostaining of PIN1 was performed on A 218 bp fragment of b-catenin encompassing the GSK-3b phosphorylation site in exon 3 was amplified by primers as reported previously (Wong et al., 2001) . PCR products were gel purified, sequenced bidirectionally with the DyEnamic ET dye sequencing kit (Amersham, Buckinghamshire, UK) and analysed on an automated DNA sequence analyzer (ABI Prism 377, PE Biosystems, Foster city, CA, USA) a Of all cases that showed PIN1 overexpression (n ¼ 37), only 20 was available for DNA sequencing b In cases negative for PIN1 expression but with b-catenin accumulation (n ¼ 5), only three cases were available for DNA sequencing, of which two revealed somatic mutations in exon 3 of the b-catenin gene.
c These six cases were known to have the b-catenin gene mutations and b-catenin accumulation, but PIN1 overexpression was not found in these six cases another six pairs of HCC samples with known b-catenin mutations (Wong et al., 2001) . PIN1 expression was not increased in all six HCC tumors in comparison with their nontumorous counterpart. Therefore, PIN1 overexpression and b-catenin mutations appeared to be mutually exclusive events in HCC. The accumulation of b-catenin in HCC could thus be mediated mainly by two distinct mechanisms: (1) PIN1 overexpression without b-catenin gene mutation and (2) b-catenin gene mutation when PIN1 was not overexpressed. Both pathologic processes contributed to the stabilization of b-catenin. The AXIN1 and AXIN2 genes in these samples were also sequenced, but no mutation was identified (data not shown).
The upregulation of b-catenin and cyclin D1 has been well documented in HCC (Nishida et al., 1994; de La Coste et al., 1998) . Previous studies have shown that bcatenin is overexpressed in about 70% of HCC (Ihara et al., 1996; Huang et al., 1999) , although only about 10-20% of these cases show b-catenin gene mutations (de La Coste et al., 1998; Miyoshi et al., 1998; Wong et al., 2001) . Cyclin D1 gene amplification was reported in less than 15% of HCC patients (Zhang et al., 1993; Nishida et al., 1994) , but overexpressions of cyclin D1 mRNA and cyclin D1 protein were reported in up to 22% (Nishida et al., 1994) and 58% (Joo et al., 2001) of HCC, respectively. These results suggest that additional mechanisms are involved in upregulating the b-catenin and cyclin D1 levels observed in HCC. In this study, we demonstrated that PIN1 expression was upregulated in HCC, which led to b-catenin and cyclin D1 accumulation. As PIN1 regulates b-catenin and cyclin D1 turnover, our finding provides new insight to the previously unexplained b-catenin accumulation and cyclin D1 overexpression in HCC. Furthermore, we showed that PIN1 overexpression and somatic mutations of b-catenin were distinct events leading to bcatenin accumulation, further underscoring the importance of PIN1 and b-catenin in hepatocarinogenesis.
It has been shown that PIN1 is strikingly overexpressed in breast cancer and that its overexpression leads to the upregulation of cyclin D1 and transformation of breast epithelial cells Ryo et al., 2003) . As PIN1 is overexpressed in over half of our studied HCC cases, a critical question is whether overexpression of PIN1 has any effect on the cell transformation of hepatocytes. Using in vitro transfection experiment, MIHA cells stably transfected with PIN1 conferred anchorage-independent cell growth in soft agar and formed tumors in nude mice by subcutaneous injection, while parental MIHA or MIHA-vector-transfected control did not (RP and ET, unpublished data) . These results provided further evidence that PIN1 is important in the pathogenesis of HCC.
The mechanisms by which PIN1 is upregulated in HCC remain to be determined. Nevertheless, recent data have shown that deregulation of E2F plays a key role in the upregulation of PIN1 in breast cancer . Since deregulation of the retinoblastoma pathway has also been reported in HCC (Santoni-Rugiu et al., 1998) , deregulation of the Rb/E2F pathway may be responsible for PIN1 overexpression in HCC.
In summary, our data provide evidence that PIN1 is critically involved in hepatocarcinogenesis via deregulation of b-catenin and cyclin D1. Since PIN1 is an enzyme having an extraordinarily high substrate specificity and well-defined active site, it is an ideal target that can potentially be exploited for therapeutic intervention. , and cloned into a pGEM vector under the transcriptional control of a B600 bp fragment of the albumin gene promoter (a kind gift from Dr J Liang, National Institutes of Health, Bethesda, MD, USA) to give the plasmid pPIN1 (Manickan et al., 2001) . The PIN1 cDNA clone was sequenced bidirectionally for sequence confirmation. Empty plasmid pGEM was used as a transfection control. A nontumorigenic, immortalized liver cell line, MIHA (a gift kindly provided by Dr J Roy-Chowdhury, Albert Einstein College of Medicine), was used for transfection experiments (Brown et al., 2000) . Cells were transfected with 5.25 mg of pPIN1 or pGEM with FuGENE 6 according to the manufacturer's protocol (Boehringer, Mannhein, GmbH, Germany). At 2 days post-transfection, the medium was replaced with fresh Waymouth's medium (Gibco/BRL) containing Geneticin (G418) at 1 mg/ml for clonal selection. Selection was maintained in a medium containing G418 at 0.5 mg/ml to ensure a stable transfection. Isolated clones were expanded in 25 cm flasks. All the transfected cells used in this experiment were in early passages. Western blot analysis showing the expression levels of the three proteins for empty vector and PIN1 transfectants (MIHA-PIN1). The protein levels of PIN1, bcatenin and cyclin D1 were significantly increased in PIN1-transfected cells as compared with the vector-transfected control (MIHA-Vector). Huh-7 is an HCC cell line that served as a positive control. b-actin serves as an internal control. Transient transfection of MIHA with pPIN1 and the relevant control plasmids were also performed. The cells were harvested 24 h post-transfection for Western blot analysis and the same results as that with stable transfection were obtained. (b) Correlation between levels of PIN1 and b-catenin in MIHA cells stably transfected with pPIN1. The protein levels of PIN1 and b-catenin were assessed by Western blot in three different MIHA clones (clones 1-3). With the increasing expression levels of PIN1 from clones 1 to 3, there was a corresponding increase in b-catenin levels in the respective clones
